Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1621 1627 1654 1658 1671 1676 1799
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19329358 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18121499 | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | Non-Final OA | BAYER HEALTHCARE LLC |
| 18259500 | HALF-LIFE EXTENDING MOIETIES AND METHODS OF USING THE SAME | Non-Final OA | Eli Lilly and Company |
| 18015927 | NOVEL PEPTOID COMPOUNDS THAT BIND TO CELL RECEPTOR ACE2 AND PREVENT VIRUS ENTRY INTO CELLS | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 17625314 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) LIGANDS | Non-Final OA | NANYANG TECHNOLOGICAL UNIVERSITY |
| 18004545 | SARS-COV-2 inhibitors | Non-Final OA | WASHINGTON UNIVERSITY |
| 17762384 | DOLASTATIN 10 ANALOG | Non-Final OA | Ariel Scientific Innovations Ltd. |
| 17645836 | CYCLIC PEPTIDE PRODUCTION METHOD | Non-Final OA | AJINOMOTO CO., INC. |
| 17801115 | DIGESTIVE FLUID LEAK PREVENTATIVE MATERIAL AND ORGAN PROTECTIVE MATERIAL AGAINST DIGESTION BY DIGESTIVE FLUID | Final Rejection | OSAKA UNIVERSITY |
| 18011354 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | Non-Final OA | Stealth Biotherapeutics Inc. |
| 17616033 | METHODS AND COMPOSITIONS FOR CLEANING | Non-Final OA | DANISCO US INC |
| 18032076 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS | Final Rejection | HANMI PHARM CO., LTD. |
| 17998337 | SURFACTANT PROTEIN C MIMICS DISPLAYING PATHOGEN- OR ALLERGEN-BINDING MOIETIES | Non-Final OA | MAXWELL BIOSCIENCES, INC. |
| 17906555 | ORAL PHARMACEUTICAL COMPOSITION | Non-Final OA | XIZANG HAISCO PHARMACEUTICAL CO., LTD. |
| 18254782 | PEPTIDES AND USES THEREOF IN MODULATION OF AMYLOID-BETA PROTEIN DEGRADING PROTEASES | Non-Final OA | MONASH UNIVERSITY |
| 18017693 | GLP-1 RECEPTOR ANTAGONISTS | Non-Final OA | NXERA PHARMA UK LIMITED |
| 18281700 | METHODS OF TREATING MYOTONIC DYSTROPHY TYPE 1 USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | Non-Final OA | PepGen Inc. |
| 18279961 | APPLICATION OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 2 IN PREPARATION OF DRUGS FOR RESISTING MENTAL DISORDERS CAUSED BY EARLY LIFE STRESS | Non-Final OA | SHANGHAI MENTAL HEALTH CENTER (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENTER) |
| 18548413 | COLLAGENOUS EXTRACTS FOR USE AS A MEDICAMENT | Non-Final OA | JELLAGEN LTD |
| 18451003 | POLYPEPTIDES INCLUDING A BETA-TRICALCIUM PHOSPHATE-BINDING SEQUENCE AND USES THEREOF | Non-Final OA | THERADAPTIVE, INC. |
| 18264425 | PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIC SELF-ASSEMBLING PEPTIDE RADA16 FOR TREATING OR PREVENTING LOWER GASTROINTESTINAL DISEASES SUCH AS INFLAMMATORY BOWEL DISEASE | Non-Final OA | Gunma University |
| 17290767 | APPLICATION OF ECM1 IN PREVENTION AND/OR TREATMENT OF LIVER FIBROSIS-RELATED DISEASES | Non-Final OA | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 18254327 | COMPOUNDS FOR TREATING ENVELOPED VIRUS INFECTIONS | Non-Final OA | Progelife |
| 18250829 | POLYPEPTIDES HAVING ANTI-INFLAMMATORY EFFECTS AND USES THEREOF | Non-Final OA | UNIÃO BRASILEIRA DE EDUCAÇÃO CATÓLICA, BRASÍLIA |
| 18174730 | USE OF PEPTIDES AS THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES AND BONE DISEASES | Non-Final OA | KINE SCIENCES CO., LTD. |
| 18009652 | SYNTHESIS OF A GUANYLATE CYCLASE AGONIST BY FRAGMENTS BASED APPROACH | Non-Final OA | ANTHEM BIOSCIENCES PRIVATE LIMITED |
| 17927625 | AN INTERLEUKIN-1 RECEPTOR ANTAGONIST AND A FUSION PROTEIN CONTAINING THE SAME | Final Rejection | BEIJING VDJBIO CO., LTD. |
| 17917283 | NOVEL ANTIBACTERIAL PEPTIDE OR PEPTIDE ANALOG AND USE THEREOF | Non-Final OA | CAMP THERAPEUTICS INC. |
| 17918573 | CELL-DERIVED VESICLES COMPRISING WILD-TYPE P53 PROTEIN FOR ANTIVIRAL THERAPY | Final Rejection | Exoprother Medical Ltd. |
| 17910364 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS | Non-Final OA | BioLineRx Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy